Circadian, a biotechnology drug developer with a focus on oncology products, has submitted an Investigational New Drug (IND) application to the FDA to begin Phase I trials of their lead anti-cancer compound VGX-100.
VGX-100 is a human antibody that acts against the human VEGF-C protein (Vascular Endothelial Growth Factor-C). Preclinical studies suggest that when VGX-100 is combined with Avastin and chemotherapy, it can substantially reduce tumor growth and spread better than Avastin or chemotherapy can achieve on their own.
VEGF-C has been identified as a key mediator of disease progression during Avastin therapy. This has led the company to believe that, Avastin, combined with VGX-100 could lead to much better treatment outcomes in patients with cancer.
Circadian will initially target both metastatic colorectal cancer and glioblastoma with VGX-100, but will likely test it in other indications as well.
Further Information
Circadian.com.au
